Pharsight

Drug patents opposed in 2021

Drug patents opposed in 2021 at the European Patent Office (EPO).

Patent Number Patent Title Company Recent Opposition Date Recent Opposition By Activity Alert
EP2729151B1 Pharmaceutical composition, methods for treating and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH 28 Dec, 2021
(Expiration: Jul, 2032)
GENERICS UK
(and 1 more)
EP3214058B1 Use of magnesium fluoride sintered compact as neutron moderator UNIVERSITY OF TSUKUBA NUC 28 Dec, 2021
(Expiration: May, 2034)
NIKKEI SANGYO
EP3277718B1 Dosage regimen for anti-mif antibodies BAXALTA GMBH 24 Dec, 2021
(Expiration: Mar, 2036)
SCORPIO
EP3329018B1 Il-6 antagonists for use in treating hepcidin-mediated disorders MEDIMMUNE LTD 24 Dec, 2021
(Expiration: Jul, 2036)
STRAWMAN
EP3484585B1 Use of probiotics in the treatment and/or prevention of atopic dermatitis BIONOU RESEARCH SL 23 Dec, 2021
(Expiration: Jul, 2037)
CHR HANSEN
EP3200591B1 Central memory t cells for adoptive t cell therapy CITY OF HOPE 23 Dec, 2021
(Expiration: Sep, 2035)
PATENT BOUTIQUE
(and 1 more)
EP3218406B1 Binding molecules specific for cd73 and uses thereof MEDIMMUNE LTD 23 Dec, 2021
(Expiration: Nov, 2035)
ROTH
(and 1 more)
EP3288561B1 Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction BOEHRINGER INGELHEIM INTERNATIONAL GMBH 23 Dec, 2021
(Expiration: Apr, 2036)
SANDOZ
EP2234617B1 Dosing regimen associated with long acting injectable paliperidone esters JANSSEN PHARMACEUTICA NV 22 Dec, 2021
(Expiration: Dec, 2028)
HOFFMANN EITLE
(and 19 more)
EP2985027B1 Nasal composition comprising mixture of hyaluronic acids and saline solution CHURCH AND DWIGHT CO INC 22 Dec, 2021
(Expiration: Aug, 2034)
PATENTANWALT DIPL ING DIETZE
EP3246017B1 Stable liquid formulation of amg 416 hcl (etelcalcetide) AMGEN INC 22 Dec, 2021
(Expiration: Jun, 2034)
STADA ARZNEIMITTEL
(and 3 more)
EP3256569B1 Alveolar-like macrophages and method of generating same HOSPITAL FOR SICK CHILDREN HSC 22 Dec, 2021
(Expiration: Feb, 2036)
STRAWMAN
EP2753310B1 Formulation for the controlled release of one or several substances in the digestive tract of a mammal INDIVIDUAL 21 Dec, 2021
(Expiration: Sep, 2032)
ELKINGTON AND FIFE
EP3173071B1 Maropitant formulation LE VET BV 20 Dec, 2021
(Expiration: Nov, 2036)
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
(and 1 more)
EP2512436B1 Conditioning composition for hair KAO GERMANY GMBH 17 Dec, 2021
(Expiration: Dec, 2030)
HENKEL
EP2421578B1 Assembly, device kit and method for preparing platelet-rich plasma (prp) INDIVIDUAL 17 Dec, 2021
(Expiration: Apr, 2030)
REGEN LAB
EP3377103B1 Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells REVITOPE LTD 16 Dec, 2021
(Expiration: Nov, 2036)
CHERRY BIOLABS
(and 1 more)
EP3134084B1 Method of treating lung adenocarcinoma EXELIXIS INC 16 Dec, 2021
(Expiration: Apr, 2035)
GENERICS UK
EP2988830B1 Composition for straightening keratin fibres, comprising a urea and/or a urea derivative and a nonionic, cationic, amphoteric or anionic associative polymeric thickener, process and use thereof LOREAL SA 15 Dec, 2021
(Expiration: Apr, 2034)
BEIERSDORF
EP3554461B1 Cosmetic composition comprising solid fatty substances and a gelling polymer LOREAL SA 15 Dec, 2021
(Expiration: Dec, 2037)
HENKEL
(and 2 more)
EP3318255B1 Compositions and methods for treating stroke in a subject on concomitant statin therapy AMARIN PHARMACEUTICALS IRELAND LTD 10 Dec, 2021
(Expiration: Jun, 2030)
COOKE
(and 2 more)
EP2516330B1 Particulate titanium dioxide CRODA INTERNATIONAL PLC 10 Dec, 2021
(Expiration: Dec, 2030)
DSM NUTRITIONAL PRODUCTS
EP3313874B1 Masking chimeric antigen receptor t cells for tumor-specific activation UNIVERSITY OF SOUTHERN CALIFORNIA USC 10 Dec, 2021
(Expiration: Jun, 2036)
JAMES POOLE
EP3604339B1 Therapeutic antibodies against ror-1 protein and methods for use of same UNIVERSITY OF CALIFORNIA 10 Dec, 2021
(Expiration: Jan, 2032)
JG OPPOSITIONS
EP2806914B1 A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp) ESTAR TECHNOLOGIES LTD 10 Dec, 2021
(Expiration: Jan, 2033)
REGEN LAB
EP3200605B1 Labyrinthulomycetes biomass with high exopolysaccharide- and so4-content and its use in the production of animal feed EVONIK OPERATIONS GMBH 09 Dec, 2021
(Expiration: Oct, 2035)
ABEL & IMRAY
EP3200602B1 Pufa-containing biomass with high cell stability and its use in the production of animal feed EVONIK OPERATIONS GMBH 09 Dec, 2021
(Expiration: Sep, 2035)
ABEL & IMRAY
EP3061454B1 Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC 09 Dec, 2021
(Expiration: Jan, 2033)
KRKA
(and 1 more)
EP3562465B2 Novel antioxidants for cosmetics and pharmaceutical compositions containing glycerol alkyl ethers SACHEM INC 08 Dec, 2021
(Expiration: Dec, 2037)
HENKEL
EP3288980B1 Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody BRISTOL MYERS SQUIBB CO 08 Dec, 2021
(Expiration: Apr, 2036)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
(and 4 more)
EP3139904B1 Formulation of fat-soluble vitamin BASF SE 03 Dec, 2021
(Expiration: May, 2035)
DSM NUTRITIONAL PRODUCTS
EP3378486B1 Stabilized antibody-containing liquid formulations CHUGAI PHARMACEUTICAL CO LTD 03 Dec, 2021
(Expiration: Jan, 2031)
ELKINGTON AND FIFE
(and 4 more)
EP3592432B1 Gardenia extract used for coloring keratin fibers PIERRE FABRE DERMO COSMETIQUE SA 03 Dec, 2021
(Expiration: Mar, 2038)
HENKEL
EP3153155B1 Refillable drug delivery devices and methods of use thereof HARVARD COLLEGE 03 Dec, 2021
(Expiration: Sep, 2036)
JAMES POOLE
EP2968155B1 Tofacitinib oral sustained release dosage forms PFIZER INC 03 Dec, 2021
(Expiration: Mar, 2034)
STADA ARZNEIMITTEL
(and 5 more)
EP3028691B1 Ceramide dispersion composition FUJIFILM CORP 02 Dec, 2021
(Expiration: Jun, 2034)
EVONIK INDUSTRIES
(and 1 more)
EP2797574B1 Oxidative dyeing composition KAO GERMANY GMBH 02 Dec, 2021
(Expiration: Dec, 2032)
HENKEL
EP3398444B1 Method to convert insects or worms into nutrient streams and compositions obtained thereby BUEHLER INSECT TECHNOLOGY SOLUTIONS AG 02 Dec, 2021
(Expiration: Jun, 2033)
YNSECT
(and 2 more)
EP3197493B1 Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent AVEO PHARMACEUTICALS INC 29 Nov, 2021
(Expiration: Sep, 2035)
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
EP3484437B1 Dentifrice including zinc and blue dye or pigment COLGATE PALMOLIVE CO 26 Nov, 2021
(Expiration: Aug, 2036)
UNILEVER UNILEVER
EP3405495B1 Neutralization of inhibitory pathways in lymphocytes INNATE PHARMA SAS 24 Nov, 2021
(Expiration: Jan, 2037)
HIBERG PS
EP3442491B1 Surface modified effect pigment and nail varnish composition ECKART GMBH 24 Nov, 2021
(Expiration: Apr, 2037)
SCHLENK METALLIC PIGMENTS
EP3293202B2 Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof CANTARGIA AB 24 Nov, 2021
(Expiration: Mar, 2035)
ZWICKER SCHNAPPAUF & PARTNER PATENTANWLTE PARTG MBB
(and 2 more)
EP3197427B1 O/w emulsions DSM IP ASSETS BV 23 Nov, 2021
(Expiration: Sep, 2035)
DALLI WERKE
EP3450434B1 Deuterated derivatives of ruxolitinib CONCERT PHARMACEUTICALS INC 23 Nov, 2021
(Expiration: Jun, 2033)
INCYTE
EP3549601B1 Non-lipidated variants of neisseria meningitidis orf2086 antigens WYETH LLC 23 Nov, 2021
(Expiration: Sep, 2031)
JG OPPOSITIONS
EP2275132B1 Multivalent PCV2 immunogenic compositions and methods of producing them BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC 22 Nov, 2021
(Expiration: Dec, 2026)
ELANCO
(and 2 more)
EP2858679B1 Pulmonary delivery of mrna to non-lung target cells ETHRIS GMBH 22 Nov, 2021
(Expiration: Jun, 2033)
FRKELLY
EP3329909B1 Fenfluramine for use in the treatment of dravet syndrome UNIVERSITY HOSPITAL ANTWERP 22 Nov, 2021
(Expiration: May, 2034)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
(and 1 more)
EP3134123B1 Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody NEKTAR THERAPEUTICS INDIA PVT LTD 17 Nov, 2021
(Expiration: Feb, 2035)
GREINER
EP3544976B1 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof AICURIS GMBH AND CO KG 17 Nov, 2021
(Expiration: Nov, 2037)
INNOVATIVE MOLECULES
EP3177645B1 Subcutaneously administered bispecific antibodies for use in the treatment of cancer LINDIS BIOTECH GMBH 17 Nov, 2021
(Expiration: Aug, 2035)
MORPHOSYS
(and 9 more)
EP3331894B1 Nicotinamide mononucleotide derivatives and their uses METRO INTERNATIONAL BIOTECH LLC 17 Nov, 2021
(Expiration: Aug, 2036)
PLASSERAUD
EP3071206B1 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis CL BIOSCIENCES LLC 17 Nov, 2021
(Expiration: Nov, 2034)
TRIO MEDICINES
EP3019198B1 Compositions and methods for improving rebaudioside m solubility PURECIRCLE SDN BHD 16 Nov, 2021
(Expiration: Jul, 2034)
EISENFHR SPEISER
(and 1 more)
EP3600486B1 Carbohydrate composition for dialysis OPTERION HEALTH AG 16 Nov, 2021
(Expiration: Mar, 2038)
FRESENIUS KABI DEUTSCHLAND
EP3461472B2 Sensitive skin cleanser with enhanced cleaning effect PETER GREVEN PHYSIODERM GMBH 16 Nov, 2021
(Expiration: Oct, 2038)
HENKEL
EP3320902B1 Methods for treating diseases using isoindoline compounds AMGEN EUROPE GMBH 16 Nov, 2021
(Expiration: Mar, 2032)
TEVA PHARMACEUTICAL INDUSTRIES
EP3651862B1 High glycerol composition comprising blends of alkyl isethionate and alkyl taurate UNILEVER PLC 15 Nov, 2021
(Expiration: May, 2038)
HENKEL
EP3515400B1 Compositions comprising specific surfactants and high levels of glycerin UNILEVER PLC 12 Nov, 2021
(Expiration: Sep, 2037)
HENKEL
EP3401335B1 Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof GENENTECH INC 08 Nov, 2021
(Expiration: Jan, 2029)
HEXAL
(and 4 more)
EP3030214B2 Alcoholic sunscreen gel BEIERSDORF AG 05 Nov, 2021
(Expiration: Jun, 2034)
HENKEL
(and 1 more)
EP3616680B1 Compound containing basic dye and amino acid, hair dying dye, and hair dying composition HODOGAYA CHEMICAL CO LTD 05 Nov, 2021
(Expiration: Aug, 2039)
HENKEL
EP3102186B1 Donepezil compositions and method of treating alzheimer's disease FOREST LABORATORIES HOLDINGS LTD 27 Oct, 2021
(Expiration: Feb, 2035)
BLLE DR
EP2944306B1 Vegf antagonist formulations suitable for intravitreal administration REGENERON PHARMACEUTICALS INC 27 Oct, 2021
(Expiration: Jun, 2027)
BOULT WADE TENNANT
(and 2 more)
EP3169308B1 Suspension compositions of cyclosporin a for subconjunctival and periocular injection ALLERGAN INC 27 Oct, 2021
(Expiration: Jul, 2035)
GILL JENNINGS & EVERY
EP3525781B1 Composition comprising epa and dha for an enhanced efficacy of anticancer agents FRESENIUS KABI DEUTSCHLAND GMBH 27 Oct, 2021
(Expiration: Oct, 2037)
NUTRICIA
EP2993999B1 Nicotine salt formulations for electronic cigarettes and method of delivering nicotine JUUL LABS INC 27 Oct, 2021
(Expiration: May, 2034)
PHILIP MORRIS PRODUCTS
(and 2 more)
EP3220752B1 Use of whey protein micelles and polysaccharides for improving insulin profile SOCIETE DES PRODUITS NESTLE SA 26 Oct, 2021
(Expiration: Nov, 2035)
FRESENIUS KABI DEUTSCHLAND
EP3283179B1 Solid skin care emulsion comprising solid and liquid lipids BEIERSDORF AG 26 Oct, 2021
(Expiration: Mar, 2036)
HENKEL
EP3082858B1 Adrenomedullin binder for use in therapy of cancer ANGIOBIOMED GMBH 26 Oct, 2021
(Expiration: Dec, 2034)
SCHIWECK WEINZIERL KOCH PATENTANWLTE PARTNERSCHAFT MBB
EP3215171B1 Enteral nutrition composition EVEN SANTE INDUSTRIE SAS 25 Oct, 2021
(Expiration: Nov, 2035)
NUTRICIA
(and 1 more)
EP2952177B1 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators NOVARTIS AG 20 Oct, 2021
(Expiration: Oct, 2028)
ACCORD HEALTHCARE
EP3370770B1 Subcutaneous formulations of anti-cd38 antibodies and their uses JANSSEN BIOTECH INC 20 Oct, 2021
(Expiration: Nov, 2036)
BREUER
(and 2 more)
EP3402455B1 Cosmetic compositions containing benzethonium-chloride and diols BEIERSDORF AG 20 Oct, 2021
(Expiration: Dec, 2036)
LORAL
EP3616720B1 Pharmaceutical composition for cancer treatment OSAKA UNIVERSITY NUC 14 Oct, 2021
(Expiration: Mar, 2038)
KNIG SZYNKA TILMANN VON RENESSE
(and 9 more)
EP3102208B1 Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde GLOBAL BLOOD THERAPEUTICS INC 13 Oct, 2021
(Expiration: Feb, 2035)
BLLE DR
EP3393441B1 Dyeing composition comprising a direct dye of triarylmethane structure, and a silicone LOREAL SA 13 Oct, 2021
(Expiration: Dec, 2036)
HENKEL
EP3310349B1 Compositions and methods for enhancing neurogenesis in animals SOCIETE DES PRODUITS NESTLE SA 13 Oct, 2021
(Expiration: Jun, 2036)
NUTRICIA
(and 1 more)
EP3113756B2 Abrasive skin cleaning products i BEIERSDORF AG 11 Oct, 2021
(Expiration: Feb, 2035)
HENKEL
EP3322731B1 Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) BRISTOL MYERS SQUIBB CO 07 Oct, 2021
(Expiration: Jul, 2036)
REGENERON PHARMACEUTICALS
(and 8 more)
EP2872171B1 Toxicity management for anti-tumor activity of cars CHILDRENS HOSPITAL OF PHILADELPHIA CHOP 06 Oct, 2021
(Expiration: Jul, 2033)
GEDEON RICHTER PHARMA
(and 3 more)
EP3031907B1 Materials and methods to enhance hematopoietic stem cells engraftment procedures INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP 06 Oct, 2021
(Expiration: Nov, 2029)
JAMES POOLE
EP3111942B1 Compositions for use in the prevention or treatment of urt infections in infants or young children at risk SOCIETE DES PRODUITS NESTLE SA 06 Oct, 2021
(Expiration: Nov, 2034)
NUTRICIA
EP3068404B1 Compositions for use in the prevention or treatment of urt infections in infants or young children at risk SOCIETE DES PRODUITS NESTLE SA 06 Oct, 2021
(Expiration: Nov, 2034)
NUTRICIA
EP3322487B1 Magnolia bark extract as a hydrophobic ligand for preferential removal of gram negative bacteria from the oral cavity WM WRIGLEY JR CO 06 Oct, 2021
(Expiration: Jul, 2036)
PERFETTI VAN MELLE
EP3377110B1 Nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined degree of polymerization ABBVIE DEUTSCHLAND GMBH AND CO KG 06 Oct, 2021
(Expiration: Oct, 2036)
SINTEF TTO
EP3550985B1 Nutritional composition for improving cell membranes NUTRICIA NV 06 Oct, 2021
(Expiration: Dec, 2037)
SOCIT DES PRODUITS NESTL
EP2359701B1 Composition for improving membrane composition and functioning of cells for use in the treatment of allergy NUTRICIA NV 06 Oct, 2021
(Expiration: Dec, 2026)
STRAWMAN
(and 3 more)
EP3377049B1 Crystalline forms of tapentadol salts and process for preparation thereof MSN LABORATORIES PVT LTD 06 Oct, 2021
(Expiration: Nov, 2036)
URQUHART DYKES & LORD
EP2345410B1 Pharmaceutical composition for modified release ASTELLAS PHARMA INC 30 Sep, 2021
(Expiration: Sep, 2029)
BRAND MURRAY FULLER
(and 5 more)
EP2874507B1 Aqueous transparent oil-in-water emulsion comprising an emulsified carotenoid BASF SE 30 Sep, 2021
(Expiration: Jul, 2033)
CHR HANSEN NATURAL COLORS
EP3453686B1 Use of a lithium silicate glass ceramic with zro2 content IVOCLAR VIVADENT AG 30 Sep, 2021
(Expiration: Apr, 2031)
DENTSPLY SIRONA
EP3547992B1 Mixtures comprising a phenyl alkanol and a linear alcohol with 8 to 12 carbon atoms SYMRISE AG 30 Sep, 2021
(Expiration: Nov, 2037)
FIRMENICH
EP3478322B1 Methods and compounds for the treatment or prevention of severe influenza HVIVO SERVICES LTD 30 Sep, 2021
(Expiration: Jun, 2037)
GILL JENNINGS & EVERY
EP3359561B1 Modulators of complement function INDIVIDUAL 29 Sep, 2021
(Expiration: Dec, 2036)
ALGEMEEN OCTROOI EN MERKENBUREAU
EP3389618B1 Process for treating keratin fibres using an aqueous composition comprising a combination of particular alkoxysilanes LOREAL SA 29 Sep, 2021
(Expiration: Dec, 2036)
HENKEL
EP3246044B1 Stable formulations of neisseria meningitidis rlp2086 antigens WYETH LLC 29 Sep, 2021
(Expiration: Aug, 2031)
SANOFI PASTEUR
EP2925324B1 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating primary negative symptoms of schizophrenia RICHTER GEDEON NYRT 29 Sep, 2021
(Expiration: Nov, 2033)
WITTKOPP
(and 1 more)
EP3366283B1 Direct compression formulation and process NOVARTIS AG 28 Sep, 2021
(Expiration: Jan, 2025)
COOKE
(and 5 more)
EP3503867B1 Transparent cosmetic cleansing composition with improved rheological profil HENKEL AG AND CO KGAA 24 Sep, 2021
(Expiration: Jul, 2037)
CRODA
(and 1 more)
EP3240612B1 Methods of treating retinal diseases CELL CURE NEUROSCIENCES LTD 23 Sep, 2021
(Expiration: Apr, 2035)
JAMES POOLE
(and 1 more)
EP3335736B1 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS INC 23 Sep, 2021
(Expiration: Nov, 2027)
LEWIS SILKIN
(and 2 more)
EP2729126B1 Liposomes having useful n:p ratio for delivery of rna molecules GLAXOSMITHKLINE BIOLOGICALS SA 23 Sep, 2021
(Expiration: Jul, 2032)
MLLER
(and 3 more)
EP3216463B1 Solid preparation containing alkyl cellulose and method for producing the same SHIN ETSU CHEMICAL CO LTD 22 Sep, 2021
(Expiration: Feb, 2037)
DUPONT NUTRITION BIOSCIENCES APS
EP3622946B2 Cosmetic hair composition made of aloe vera and coconut oil and method for preparing same LABORATOIRES LEA SAS 21 Sep, 2021
(Expiration: Sep, 2039)
HENKEL
EP3522921B1 Prevention of allergy ASIT BIOTECH SA 21 Sep, 2021
(Expiration: Oct, 2037)
NUTRICIA
EP3177150B1 A combination of vitamin d and zinc and its use SOCIETE DES PRODUITS NESTLE SA 20 Sep, 2021
(Expiration: Aug, 2035)
ABBOTT LABORATORIES
(and 2 more)
EP3215231B1 Capsule composition GIVAUDAN SA 16 Sep, 2021
(Expiration: Oct, 2035)
THE PROCTER & GAMBLE
(and 1 more)
EP3411057B2 High caloric, high protein nutritional formula comprising collagen FRESENIUS KABI DEUTSCHLAND GMBH 15 Sep, 2021
(Expiration: Feb, 2037)
NUTRICIA
EP2545939B1 Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels BIOMARIN PHARMACEUTICAL INC 14 Sep, 2021
(Expiration: Apr, 2028)
STADA ARZNEIMITTEL
(and 4 more)
EP3209295B2 Methods of treating ocular conditions OYSTER POINT PHARMA INC 09 Sep, 2021
(Expiration: Oct, 2035)
BECK GREENER
EP3256573B1 Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography UNIVERSITE DE NANTES 09 Sep, 2021
(Expiration: Feb, 2036)
D YOUNG
EP3103469B1 Cns delivery of therapeutic agents SHIRE HUMAN GENETICS THERAPIES INC 09 Sep, 2021
(Expiration: Jun, 2031)
GREEN CROSS
EP3337467B1 Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment IPSEN BIOPHARM LTD 09 Sep, 2021
(Expiration: Aug, 2036)
SANDOZ
EP3345625B1 Pharmaceutical composition and administrations thereof VERTEX PHARMACEUTICALS INC 09 Sep, 2021
(Expiration: Aug, 2029)
STADA ARZNEIMITTEL
(and 2 more)
EP2356914B1 Composition for improving membrane composition and functioning of cells NUTRICIA NV 06 Sep, 2021
(Expiration: Dec, 2026)
ABBOTT LABORATORIES
(and 1 more)
EP3363433B1 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester AMARIN PHARMACEUTICALS IRELAND LTD 03 Sep, 2021
(Expiration: Jun, 2033)
ELKINGTON AND FIFE
(and 2 more)
EP2734217B1 Product for parenteral feeding of obese intensive care patients FRESENIUS KABI DEUTSCHLAND GMBH 02 Sep, 2021
(Expiration: Jul, 2032)
B BRAUN MELSUNGEN
EP3204022B1 Placenta-derived adherent cell exosomes and uses thereof CELULARITY INC 02 Sep, 2021
(Expiration: Oct, 2035)
D YOUNG
EP3172209B1 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide NOVARTIS AG 01 Sep, 2021
(Expiration: Jul, 2035)
D YOUNG
EP3275424B1 Composition to reduce the drying time of keratin fibers, method and use thereof KAO GERMANY GMBH 01 Sep, 2021
(Expiration: Jul, 2036)
HENKEL
EP3400943B1 Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer ARRAY BIOPHARMA INC 01 Sep, 2021
(Expiration: Mar, 2033)
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
EP3437513B1 Nonwoven sheet for facial mask KOLON INDUSTRIES INC 31 Aug, 2021
(Expiration: Apr, 2037)
CARL FREUDENBERG
EP3256574B1 Recombinant adeno-associated virus particle purification comprising an affinity purification step UNIVERSITE DE NANTES 25 Aug, 2021
(Expiration: Feb, 2036)
J A KEMP
(and 6 more)
EP3154567B1 Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy POLYBIOCEPT GMBH 25 Aug, 2021
(Expiration: Jun, 2035)
MARGARET DIXON
(and 1 more)
EP3482770B1 Immunogenic compositions GLAXOSMITHKLINE BIOLOGICALS SA 25 Aug, 2021
(Expiration: Oct, 2033)
PFIZER
EP3226842B1 Anticancer compositions ARAGON PHARMACEUTICALS INC 24 Aug, 2021
(Expiration: Dec, 2035)
ALFRED E TIEFENBACHER
(and 1 more)
EP3079714B1 Long lasting effect of new botulinum toxin formulations MEDY TOX INC 24 Aug, 2021
(Expiration: Dec, 2034)
GALDERMA HOLDING
EP3228315B1 Prevention of adverse effects caused by cd3 specific binding domains AMGEN RESEARCH MUNICH GMBH 24 Aug, 2021
(Expiration: Oct, 2031)
JAMES POOLE
(and 1 more)
EP3551181B1 Treatment comprising oral or gastric administration of edaravone TREEWAY TW001 BV 18 Aug, 2021
(Expiration: Jan, 2038)
BARDEHLE PAGENBERG PARTNERSCHAFT MBB PATENTANWLTE
EP3659594B1 A sterile solution with an application injector comprising a medical agent and method for producing same INDIVIDUAL 18 Aug, 2021
(Expiration: Nov, 2038)
HEPP WENGER RYFFEL
EP3461484B9 Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders AERIE PHARMACEUTICALS INC 18 Aug, 2021
(Expiration: Mar, 2034)
ISARPATENT PATENT UND RECHTSANWLTE BARTH CHARLES HASSA PECKMANN UND PARTNER MBB
(and 2 more)
EP3099333B8 Bag3 as a target for therapy of heart failure TEMPLE UNIVERSITY OF COMMONWEALTH SYSTEM OF HIGHER EDUCATION 18 Aug, 2021
(Expiration: Jan, 2035)
JG OPPOSITIONS
EP3019185B1 Combination treatment for atopic dermatitis MICREOS HUMAN HEALTH BV 18 Aug, 2021
(Expiration: Jul, 2034)
SONN PATENTANWLTE
EP3307877B1 Method to treat cancer with engineered t-cells LENTIGEN TECHNOLOGY INC 17 Aug, 2021
(Expiration: Jun, 2036)
DICK
EP3372238B1 Insulin formulations for rapid uptake ELI LILLY AND CO 16 Aug, 2021
(Expiration: Mar, 2030)
SAGITTARIUS CONSULTANTS
(and 1 more)
EP3137060B2 Extended release suspension compositions SUN PHARMACEUTICAL INDUSTRIES LTD 11 Aug, 2021
(Expiration: May, 2035)
RECKITT BENCKISER HEALTH
EP3058988B1 Composition for providing a film on keratin fibres NOXELL CORP 10 Aug, 2021
(Expiration: Feb, 2036)
HENKEL
EP3461474B1 Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD 09 Aug, 2021
(Expiration: Aug, 2031)
HGF
(and 3 more)
EP3656869B1 Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling LELAND STANFORD JUNIOR UNIVERSITY 09 Aug, 2021
(Expiration: Aug, 2035)
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
EP3355701B1 Liquid nutritional composition comprising micellar casein and hydrolysed whey protein FRIESLANDCAMPINA NEDERLAND BV 04 Aug, 2021
(Expiration: Sep, 2036)
ARLA FOODS AMBA
(and 2 more)
EP3515451B2 Pharmaceutical composition MEXICHEM FLUOR SA DE CV 04 Aug, 2021
(Expiration: Sep, 2037)
BECK GREENER
EP3400291B2 Engineered virus REPLIMUNE LTD 04 Aug, 2021
(Expiration: Jan, 2037)
STRAWMAN
(and 1 more)
EP2729188B1 Compressed gas aerosol dispenser with enhanced intensity and longevity of actives SC JOHNSON AND SON INC 04 Aug, 2021
(Expiration: Jul, 2032)
THE PROCTER & GAMBLE
EP3049073B1 Compositions and method for destabilizing, altering, and dispersing biofilms UNIVERSITY OF NEWCASTLE, THE 03 Aug, 2021
(Expiration: Sep, 2034)
COLGATE PALMOLIVE
EP3449250B1 Methods and compositions for resolving components of a virus preparation UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 03 Aug, 2021
(Expiration: Apr, 2037)
DEFINITION
EP3687994B1 Gadolinium bearing pcta-based contrast agents BRACCO IMAGING SPA 02 Aug, 2021
(Expiration: Aug, 2039)
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
EP2575771B1 Composition comprising biodegradable polymers for use in a cosmetic composition MICRO POWDERS INC 02 Aug, 2021
(Expiration: May, 2031)
ECKART
EP3565521B2 O/w emulsion comprising a c16-c30 fatty alcohol, an anionic surfactant, an oil, a wax and a hydrophilic solvent LOREAL SA 02 Aug, 2021
(Expiration: Dec, 2037)
HENKEL
EP3275438B2 Methods of preventing cardiovascular events in residual risk dyslipidemic populations KOWA CO LTD 28 Jul, 2021
(Expiration: Jul, 2037)
BLLE DR
EP2818055B1 High energy liquid enteral nutritional composition NUTRICIA NV 28 Jul, 2021
(Expiration: Dec, 2028)
EVEN SANTE INDUSTRIE
(and 3 more)
EP3036256B1 Modulation of tumor immunity MERCK SHARP AND DOHME LLC 28 Jul, 2021
(Expiration: Aug, 2034)
PAJARO
(and 1 more)
EP3148576B8 Vaccine composition against streptococcus suis infection CEVA SANTE ANIMALE SA 27 Jul, 2021
(Expiration: May, 2035)
INTERVET
EP2820138B1 Retroviral transduction using poloxamers HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 27 Jul, 2021
(Expiration: Feb, 2033)
KNIG SZYNKA TILMANN VON RENESSE
EP1962797B1 Powder compositions for inhalation JAGOTEC AG 22 Jul, 2021
(Expiration: Dec, 2026)
AERA
(and 1 more)
EP2897923B1 Coloring of zirconia ceramics 3M INNOVATIVE PROPERTIES CO 21 Jul, 2021
(Expiration: Sep, 2033)
IVOCLAR VIVADENT
EP3448370B2 Composition for the treatment of polycystic ovary syndrome SOCHIM INTERNATIONAL SPA 21 Jul, 2021
(Expiration: Apr, 2037)
LOLI PHARMA
EP3259029B1 Medium chain fatty acids and their triglycerides for treating anxiety SOCIETE DES PRODUITS NESTLE SA 21 Jul, 2021
(Expiration: Feb, 2036)
NUTRICIA
EP3512486B2 Blue powder and use thereof in cosmetics LOREAL SA 20 Jul, 2021
(Expiration: Sep, 2037)
HENKEL
EP2689010B1 Method and compositions for cellular immunotherapy FRED HUTCHINSON CANCER RESEARCH CENTER 20 Jul, 2021
(Expiration: Mar, 2032)
KNIG SZYNKA TILMANN VON RENESSE
EP3007711B1 A dosing regime and formulations for type b adenoviruses PSIOXUS THERAPEUTICS LTD 19 Jul, 2021
(Expiration: Jun, 2034)
DEHNS
EP3160463B1 Intermittent dosing of mdm2 inhibitor NOVARTIS AG 16 Jul, 2021
(Expiration: Jun, 2035)
BOEHRINGER INGELHEIM
EP2994108B1 Oral pharmaceutical formulation SIEGFRIED AG 16 Jul, 2021
(Expiration: May, 2034)
EVONIK OPERATIONS
EP3107627B1 Skin cleansing compositions comprising biodegradable abrasive particles PROCTER AND GAMBLE CO 16 Jul, 2021
(Expiration: Feb, 2035)
HENKEL
(and 1 more)
EP2597969B1 Process for obtaining citrus fiber from citrus pulp CARGILL INC 14 Jul, 2021
(Expiration: Jul, 2031)
HERBSTREITH & FOX PECTIN FABRIKEN
EP2651372B2 Aerosol device having two compartments including an alcoholic or hydroalcoholic hairstyling composition, and hairstyling method LOREAL SA 13 Jul, 2021
(Expiration: Dec, 2031)
HENKEL
EP3290087B1 Spray compositions, sprayable products, and methods of treating a surface with the same PROCTER AND GAMBLE CO 13 Jul, 2021
(Expiration: Aug, 2037)
HENKEL
EP2432333B1 Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution NUTRICIA NV 12 Jul, 2021
(Expiration: May, 2030)
SOCIT DES PRODUITS NESTL
EP3566696B1 Risperidone sustained release microsphere composition SHANDONG LUYE PHARMACEUTICAL CO LTD 07 Jul, 2021
(Expiration: Apr, 2032)
ALKERMES PHARMA IRELAND
EP2921160B1 Stabilization of sunscreens in cosmetic compositions UNILEVER PLC 07 Jul, 2021
(Expiration: Mar, 2023)
BEIERSDORF
EP3294770B2 Therapeutic and diagnostic methods for cancer F HOFFMANN LA ROCHE AG 07 Jul, 2021
(Expiration: May, 2036)
GLAXOSMITHKLINE
(and 1 more)
EP3496657B1 Blank and method for producing a tooth replacement part SIRONA DENTAL SYSTEMS GMBH 07 Jul, 2021
(Expiration: Aug, 2037)
IVOCLAR VIVADENT
EP3230460B2 Methods and compositions for selectively eliminating cells of interest INDIVIDUAL 06 Jul, 2021
(Expiration: Dec, 2035)
CAMULON
EP3003360B1 High potency pancreatin pharmaceutical compositions ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD 06 Jul, 2021
(Expiration: Nov, 2034)
CAMULON
EP2885395B1 Method for freeze drying a bacteria-containing concentrate CHR HANSEN AS 06 Jul, 2021
(Expiration: Aug, 2033)
STRAWMAN
(and 2 more)
EP3558231B1 Oil-in-water emulsion and cosmetic use thereof LOREAL SA 02 Jul, 2021
(Expiration: Dec, 2037)
HENKEL
EP3525755B1 Preparation of nano-sized uv absorbers DSM IP ASSETS BV 30 Jun, 2021
(Expiration: Oct, 2037)
BASF
EP3103443B1 Method for treating primary insomnia NEURIM PHARMACEUTICALS 1991 LTD 30 Jun, 2021
(Expiration: Aug, 2022)
GENERICS UK
(and 5 more)
EP3570884B1 Subcutaneous her2 antibody formulations F HOFFMANN LA ROCHE AG 30 Jun, 2021
(Expiration: Jan, 2038)
HOFFMANN EITLE
(and 3 more)
EP3533787B1 Pyridone compound as c-met inhibitor FUJIAN COSUNTER PHARMACEUTICAL CO LTD 30 Jun, 2021
(Expiration: Oct, 2037)
MERCK PATENT
EP3090756B1 Formula of neuregulin preparation ZENSUN SHANGHAI SCIENCE AND TECHNOLOGY LTD 30 Jun, 2021
(Expiration: Dec, 2034)
STRAWMAN
EP3428193B1 Il2rbeta/common gamma chain antibodies AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH SINGAPORE 30 Jun, 2021
(Expiration: Aug, 2036)
TENEOBIO
EP3294850B1 Very long chain polyunsaturated fatty acids from natural oils EPAX NORWAY AS 29 Jun, 2021
(Expiration: May, 2036)
GOLDEN OMEGA
EP2516473B1 Anionic polysaccharides functionalised with a derivative of hydrophobic acid ADOCIA SAS 29 Jun, 2021
(Expiration: Dec, 2030)
HAMMER
EP3171868B1 Packaged acetaminophen injection solution preparation TERUMO CORP 29 Jun, 2021
(Expiration: Jul, 2034)
HOFFMANN EITLE
EP3507366B1 Chemically modified single-stranded rna-editing oligonucleotides PROQR THERAPEUTICS II BV 25 Jun, 2021
(Expiration: Aug, 2037)
MARGARET DIXON
EP3244874B2 Cosmetic composition for keratin fibers and manufacturing method thereof LOREAL SA 23 Jun, 2021
(Expiration: Dec, 2035)
HENKEL
EP1957110B8 Process for manufacturing chewable dosage forms for drug delivery and products thereof BAYER HEALTHCARE LLC 22 Jun, 2021
(Expiration: Dec, 2026)
BOEHRINGER INGELHEIM ANIMAL HEALTH USA
EP3058987B1 Composition for providing a film on keratin fibres NOXELL CORP 22 Jun, 2021
(Expiration: Feb, 2036)
HENKEL
EP3346973B1 Process for oxidative dyeing hair KAO GERMANY GMBH 22 Jun, 2021
(Expiration: Mar, 2036)
LOREAL
EP2793817B1 Bleaching and colouring composition for hair KAO GERMANY GMBH 22 Jun, 2021
(Expiration: Dec, 2032)
LOREAL
(and 1 more)
EP3390358B1 Crystalline eravacycline bis-hydrochloride SANDOZ AG 22 Jun, 2021
(Expiration: Jan, 2037)
TETRAPHASE PHARMACEUTICALS
EP3153526B1 Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM 21 Jun, 2021
(Expiration: Jan, 2029)
ABBVIE
(and 3 more)
EP3212200B1 Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 18 Jun, 2021
(Expiration: Oct, 2035)
SCHLICH
EP3117838B1 Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition SARAYA CO LTD 16 Jun, 2021
(Expiration: Mar, 2035)
DSM NUTRITIONAL PRODUCTS
EP3325013B2 Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and an angiotensin aii-antagonist and the use thereof BAYER PHARMA AG 16 Jun, 2021
(Expiration: Jul, 2036)
PAJARO
EP3155024B1 Residence structures and related methods BRIGHAM AND WOMENS HOSPITAL INC 15 Jun, 2021
(Expiration: Jun, 2035)
D YOUNG
EP2830584B1 Composition comprising (2,5-diaminophenyl)ethanol and a cellulose polymer or carboxylic anionic polymer in a medium rich in fatty substances, dyeing process and device LOREAL SA 15 Jun, 2021
(Expiration: Mar, 2033)
HENKEL
EP3307239B1 Formulations for small intestinal delivery of rsv and norovirus antigens VAXART INC 15 Jun, 2021
(Expiration: Jun, 2036)
IOSBIO
EP3188709B1 Transparent cosmetic and personal care compositions UNILEVER PLC 11 Jun, 2021
(Expiration: Aug, 2035)
HENKEL
EP3254695B1 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH 09 Jun, 2021
(Expiration: May, 2033)
DR H ULRICH DRRIES
EP3278665B1 Stable pharmaceutical composition and methods of using same AMARIN PHARMACEUTICALS IRELAND LTD 09 Jun, 2021
(Expiration: Apr, 2030)
ELKINGTON AND FIFE
EP3233258B1 Two-component products in bags for the oxidative dyeing of keratin fibres HENKEL AG AND CO KGAA 09 Jun, 2021
(Expiration: Nov, 2035)
HAMMER
EP2698431B1 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity CHUGAI PHARMACEUTICAL CO LTD 09 Jun, 2021
(Expiration: Mar, 2032)
J A KEMP
(and 1 more)
EP3270951B1 Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making CALIFORNIA INSTITUTE OF TECHNOLOGY CALTECH 09 Jun, 2021
(Expiration: Mar, 2036)
MERZ PHARMA
EP3096785B1 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof PFIZER INC 09 Jun, 2021
(Expiration: Jan, 2035)
SK BIOSCIENCE
(and 2 more)
EP3308836B1 Octocrylene-free, odour-stable sun protection agent BEIERSDORF AG 08 Jun, 2021
(Expiration: Jun, 2034)
BASF
(and 2 more)
EP2959892B1 Enteric coated tablet ZERIA PHARMACEUTICAL CO LTD 08 Jun, 2021
(Expiration: Feb, 2034)
DSM NUTRITIONAL PRODUCTS
EP3095463B1 Methods for treating progressive multiple sclerosis F HOFFMANN LA ROCHE AG 08 Jun, 2021
(Expiration: Sep, 2029)
POLPHARMA BIOLOGICS
(and 1 more)
EP2478907B1 Compositions for treating cancer JANSSEN ONCOLOGY INC 03 Jun, 2021
(Expiration: Aug, 2027)
SYNTHON
(and 21 more)
EP2809773B1 Process of modulating man5 and/or afucosylation content of glycoprotein composition DR REDDYS LABORATORIES LTD 02 Jun, 2021
(Expiration: Jan, 2033)
BREUER
(and 4 more)
EP3323413B1 Pharmaceutical composition containing celecoxib and tramadol YOO YOUNG PHARM CO LTD 02 Jun, 2021
(Expiration: Jun, 2036)
DEHMEL & BETTENHAUSEN PATENTANWLTE PARTMBB
EP3389789B1 Composition comprising the combination of specific alkoxysilanes and of a surfactant LOREAL SA 02 Jun, 2021
(Expiration: Dec, 2036)
HENKEL
EP3305285B1 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer ARAGON PHARMACEUTICALS INC 02 Jun, 2021
(Expiration: Sep, 2033)
TEVA PHARMACEUTICAL INDUSTRIES
(and 2 more)
EP2682099B1 Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists ARVEN ILAC SANAYI VE TICARET AS 01 Jun, 2021
(Expiration: Jul, 2033)
ALFRED E TIEFENBACHER
(and 2 more)
EP2981822B1 Compositions and methods for growth factor modulation SCHOLAR ROCK INC 01 Jun, 2021
(Expiration: May, 2034)
CHUGAI SEIYAKU KABUSHIKI KAISHA
EP3169320B1 A new treatment for improving the use of dietary sugar for energy purposes NUTRAVIS SRL 01 Jun, 2021
(Expiration: Jul, 2035)
EUROMED
EP3065763B2 Use of il-22 dimer in manufacture of a medicament for intravenous administration EVIVE BIOTECHNOLOGY SHANGHAI LTD 01 Jun, 2021
(Expiration: Nov, 2034)
STRAWMAN
EP3294333B1 Claudin-18.2-specific immunoreceptors and t cell epitopes TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH 31 May, 2021
(Expiration: May, 2036)
DR H ULRICH DRRIES
EP3220909B1 Bupropion for modulating drug plasma levels of dextrometorphan ANTECIP BIOVENTURES II LLC 31 May, 2021
(Expiration: May, 2035)
ELKINGTON AND FIFE
EP3348258B1 Oral and injectable formulations of tetracycline compounds PARATEK PHARMACEUTICALS INC 28 May, 2021
(Expiration: Mar, 2029)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
EP3468568B1 Human platelet lysate derived extracellular vesicles for use in medicine LYSATPHARMA GMBH 28 May, 2021
(Expiration: Jun, 2037)
UNIVERSITT DUISBURG ESSEN
EP3388048B1 Sunscreen with a reduced tendency to stain textiles iii BEIERSDORF AG 26 May, 2021
(Expiration: Apr, 2035)
BASF
EP3332773B8 Stabilized modified release vitamin d formulation and method of administering same OPKO IRELAND GLOBAL HOLDINGS LTD 26 May, 2021
(Expiration: Mar, 2034)
DSM NUTRITIONAL PRODUCTS
EP3169703B2 Chimeric antigen receptor and its use INDIVIDUAL 26 May, 2021
(Expiration: Jul, 2035)
MARGARET DIXON
EP2382228B1 Compositions and methods of treating inflammatory and autoimmune diseases AMGEN INC 26 May, 2021
(Expiration: Jan, 2030)
MERCK SHARP & DOHME
(and 3 more)
EP3370685B1 Cosmetic foam from an emulsion containing glycerin and alcohol BEIERSDORF AG 25 May, 2021
(Expiration: Oct, 2036)
HENKEL
EP3214956B1 Solution comprising nicotine in unprotonated form and protonated form NICOVENTURES HOLDINGS LTD 25 May, 2021
(Expiration: Nov, 2035)
PHILIP MORRIS PRODUCTS
EP3128993B1 Mixtures of cosmetic uv absorbers BASF SE 25 May, 2021
(Expiration: Apr, 2035)
REGIMBEAU
EP3111974B1 Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo REGEN LAB SA 18 May, 2021
(Expiration: Aug, 2027)
ESTAR
EP2970389B1 Pharmaceutical compositions RHYTHM PHARMACEUTICALS INC 18 May, 2021
(Expiration: Mar, 2034)
SANDOZ
EP2976101B1 Method of treatment GLAXOSMITHKLINE BIOLOGICALS SA 18 May, 2021
(Expiration: Mar, 2034)
SANOFI PASTEUR
EP3209673B2 Mixtures of human milk oligosaccharides GLYCOM AS 17 May, 2021
(Expiration: Oct, 2035)
CHR HANSEN HMO
(and 1 more)
EP3445344B1 Nicotine delivery product, related uses and oral dosage forms, and methods of production FERTIN PHARMA AS 17 May, 2021
(Expiration: Apr, 2036)
SIEGFRIED
EP3213750B1 Combination of two antivirals for treating hepatitis c ABBVIE INC 12 May, 2021
(Expiration: Mar, 2034)
GENERICS UK
EP3337478B1 Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer IPSEN BIOPHARM LTD 12 May, 2021
(Expiration: Aug, 2036)
GENERICS UK
(and 1 more)
EP3409286B1 Low frequency glatiramer acetate therapy YEDA RESEARCH AND DEVELOPMENT CO LTD 11 May, 2021
(Expiration: Aug, 2030)
SYNTHON
(and 1 more)
EP3068413B2 Feed supplement comprising resin acid FORCHEM OYJ 06 May, 2021
(Expiration: Nov, 2034)
GREEN INNOVATION
EP3440063B1 Aminothiazole derivatives useful as antiviral agents INNOVATIVE MOLECULES GMBH 05 May, 2021
(Expiration: Apr, 2037)
AICURIS ANTI INFECTIVE CURES
EP3566695B1 Treatment of coccidiosis with intramuscular triazine compositions CEVA SANTE ANIMALE SA 05 May, 2021
(Expiration: Dec, 2033)
ELANCO
(and 1 more)
EP3203840B1 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INC 05 May, 2021
(Expiration: Oct, 2035)
GENERICS UK
EP2872106B2 Composite pigment and method for preparing the same LOREAL SA 05 May, 2021
(Expiration: Jul, 2032)
HENKEL
EP3054929B1 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof IMPAX LABORATORIES LLC 05 May, 2021
(Expiration: Oct, 2034)
LUIGI
EP2519300B1 System for treating target tissue within the eustachian tube ACCLARENT INC 05 May, 2021
(Expiration: Dec, 2030)
SPIGGLE & THEIS MEDIZINTECHNIK
EP3351267B1 Vaccine for protection against lawsonia intracellularis INTERVET INTERNATIONAL BV 04 May, 2021
(Expiration: Apr, 2029)
CEVA SANTE ANIMALE
(and 1 more)
EP3368069B1 Use of myostatin inhibitors and combination therapies SCHOLAR ROCK INC 04 May, 2021
(Expiration: Jun, 2037)
GRUND
(and 1 more)
EP3298033B2 Compositions and medical uses for tcr reprogramming using fusion proteins TCR2 THERAPEUTICS INC 04 May, 2021
(Expiration: May, 2036)
JONES DAY
EP2992891B1 Pharmaceutical composition comprising brivaracetam and lacosamide with synergistic anticonvulsant effect UCB PHARMA GMBH 03 May, 2021
(Expiration: Jun, 2027)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
EP3127551B1 Pcv2 immunogenic composition for lessening clinical symptoms in pigs BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC 29 Apr, 2021
(Expiration: Dec, 2026)
ELANCO
(and 2 more)
EP2688587B2 Salmonid alphavirus vaccine INTERVET INTERNATIONAL BV 29 Apr, 2021
(Expiration: Mar, 2032)
ELANCO
EP3328198B1 Preservative system based on organic acids COLGATE PALMOLIVE CO 29 Apr, 2021
(Expiration: Aug, 2035)
HENKEL
EP2688549B1 Systems for custom coloration COLORIGHT LTD 29 Apr, 2021
(Expiration: Mar, 2032)
HENKEL
EP3052132B1 Antibody therapies for human immunodeficiency virus (hiv) BETH ISRAEL DEACONESS MEDICAL CENTER INC 29 Apr, 2021
(Expiration: Sep, 2034)
JAMES POOLE
EP3206716B1 Use of cannabinoids in the treatment of atonic seizures in lennox-gastaut syndrome GW RESEARCH LTD 29 Apr, 2021
(Expiration: Oct, 2035)
JAMES POOLE
EP3383385B2 Melflufen dosage regimens for cancer ONCOPEPTIDES AB 29 Apr, 2021
(Expiration: Dec, 2036)
LUIGI
(and 1 more)
EP3061448B1 Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION 27 Apr, 2021
(Expiration: Oct, 2034)
BEIERSDORF
EP3397265B1 Protein-rich enteral nutritional composition containing a high proportion of caseinates EVEN SANTE INDUSTRIE SAS 27 Apr, 2021
(Expiration: Dec, 2036)
LEIDESCHER
(and 1 more)
EP3113749B1 Abrasive skin cleaning products ii BEIERSDORF AG 23 Apr, 2021
(Expiration: Feb, 2035)
DALLI WERKE
(and 1 more)
EP3057585B1 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics SEATTLE GENETICS INC 22 Apr, 2021
(Expiration: Oct, 2034)
EUROPEAN OPPOSITIONS
EP3241550B1 (1r, 2r)-3-(dimenthyl amino-1-ethyl-2-methyl-propyl) phenol for treating painful inflammations GRUENENTHAL GMBH 22 Apr, 2021
(Expiration: Nov, 2023)
GENERICS UK
(and 3 more)
EP3389612B1 Composition intended especially for shaving the skin LOREAL SA 22 Apr, 2021
(Expiration: Dec, 2036)
HENKEL
EP3338784B1 Human milk oligosaccharides for modulating inflammation ABBOTT LABORATORIES 22 Apr, 2021
(Expiration: Dec, 2031)
NUTRICIA
(and 1 more)
EP3226895B1 Pharmaceutical product with increased stability comprising immunoglobulins CSL BEHRING AG 22 Apr, 2021
(Expiration: Dec, 2035)
OCTAPHARMA
EP3145488B1 Liquid pharmaceutical composition FRESENIUS KABI DEUTSCHLAND GMBH 22 Apr, 2021
(Expiration: May, 2035)
SAMSUNG BIOEPIS NL
(and 2 more)
EP2968172B8 Stabilized modified release vitamin d formulation and method of administring same EIRGEN PHARMA LTD 21 Apr, 2021
(Expiration: Mar, 2034)
DSM NUTRITIONAL PRODUCTS
EP3469359B1 Personalised nutrient dosing with on-going feedback loop BAZE LABS AG 21 Apr, 2021
(Expiration: May, 2037)
DSM NUTRITIONAL PRODUCTS
EP3003316B1 Combination therapies for cancer GLAXOSMITHKLINE LLC 21 Apr, 2021
(Expiration: May, 2034)
PAJARO
EP3528847B1 High-stability packaged solutions of t4 thyroid hormone ALTERGON SA 21 Apr, 2021
(Expiration: Oct, 2037)
UNI PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES
EP3013306B1 Nanocrystalline zirconia and methods of processing thereof IVOCLAR VIVADENT INC 20 Apr, 2021
(Expiration: Jun, 2034)
M DEUTSCHLAND DE M INNOVATIVE PROPERTIES
EP3344227B1 Composition comprising at least one anionic surfactant, at least two particular nonionic surfactants, at least one amphoteric surfactant and at least one particular cationic polymer LOREAL SA 19 Apr, 2021
(Expiration: Sep, 2036)
DALLI WERKE
EP3218504B1 Tri-segmented arenaviruses as vaccine vectors UNIVERSITE DE GENEVE 16 Apr, 2021
(Expiration: Nov, 2035)
DR URSULA SPRENZEL
EP3209691B1 Compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases OSE IMMUNOTHERAPEUTICS SA 15 Apr, 2021
(Expiration: Oct, 2035)
BYONDIS
EP3489211B1 Improved methods for preparing squalene NOVARTIS AG 15 Apr, 2021
(Expiration: May, 2031)
GLAXOSMITHKLINE BIOLOGICALS
EP3656765B1 Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol GRUENENTHAL GMBH 15 Apr, 2021
(Expiration: Jul, 2031)
G L PHARMA
(and 5 more)
EP3021869B1 Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors F HOFFMANN LA ROCHE AG 15 Apr, 2021
(Expiration: Jul, 2034)
JAMES POOLE
(and 2 more)
EP3260117B8 Rapid dissolution formulation comprising cinacalcet hcl AMGEN INC 14 Apr, 2021
(Expiration: Sep, 2024)
ARISTO PHARMA
(and 6 more)
EP3378900B1 Pigment powders MERCK PATENT GMBH 14 Apr, 2021
(Expiration: Mar, 2038)
BASF COLORS & EFFECTS
EP2768479B1 Excipients for nicotine-containing therapeutic compositions MODORAL BRANDS INC 14 Apr, 2021
(Expiration: Oct, 2032)
PHILIP MORRIS PRODUCTS
EP3058937B1 Composition for forming a film on keratin fibres NOXELL CORP 09 Apr, 2021
(Expiration: Feb, 2036)
HENKEL
EP2884999B1 Method and compositions for cellular immunotherapy FRED HUTCHINSON CANCER RESEARCH CENTER 09 Apr, 2021
(Expiration: Aug, 2033)
KNIG SZYNKA TILMANN VON RENESSE
EP2832858B1 Method for producing steviol glycoside SUNTORY HOLDINGS LTD 08 Apr, 2021
(Expiration: Mar, 2033)
GLEISS GROE SCHRELL UND PARTNER MBB
EP3152234B1 Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes CELLVAX 08 Apr, 2021
(Expiration: Jun, 2035)
HOFFMANN EITLE
EP3215130B1 Pharmaceutical composition comprising bisoprolol and perindoril LABORATOIRES SERVIER SAS 08 Apr, 2021
(Expiration: Nov, 2035)
KRKA
EP3348553B1 Crystalline forms of an androgen receptor modulator SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH 08 Apr, 2021
(Expiration: Jun, 2033)
SAGITTARIUS CONSULTANTS
(and 1 more)
EP2340828B1 Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor NOVARTIS AG 07 Apr, 2021
(Expiration: Nov, 2026)
SANOVEL ILA SANAYI VE TICARET ANONIM SIRKETI
(and 7 more)
EP2654736B1 Novel pharmaceutical composition NOVARTIS AG 01 Apr, 2021
(Expiration: Dec, 2031)
GENERICS UK
(and 1 more)
EP3515583B1 Fluidised bed system HUETTLIN GMBH 01 Apr, 2021
(Expiration: Jul, 2037)
GLATT GESELLSCHAFT MIT BESCHRNKTER HAFTUNG
EP3337447B2 Process for treating keratin fibres with an alkoxysilane polymer bearing a nucleophilic group and an activated (thio)ester LOREAL SA 01 Apr, 2021
(Expiration: Aug, 2036)
HENKEL
EP3215223B1 Buprenorphine dosing regimens INDIVIOR UK LTD 30 Mar, 2021
(Expiration: Nov, 2035)
ELKINGTON AND FIFE
EP3206987B1 Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof UNIVERSITY OF CHICAGO 30 Mar, 2021
(Expiration: Oct, 2035)
PLOUGMANN VINGTOFT
EP1901620B1 Phosphatidylserine enriched milk fractions for the formulation of functional foods ARLA FOODS AMBA 29 Mar, 2021
(Expiration: May, 2026)
FRIESLANDCAMPINA NEDERLAND
EP3454672B1 Uses of fermented infant formula NUTRICIA NV 29 Mar, 2021
(Expiration: May, 2037)
SOCIT DES PRODUITS NESTL
EP3461895B1 Modulation of ube3a-ats expression BAYLOR COLLEGE OF MEDICINE 26 Mar, 2021
(Expiration: Jun, 2033)
F HOFFMANN LA ROCHE
EP3144318B1 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation FERRING BV 25 Mar, 2021
(Expiration: Apr, 2029)
ARES TRADING
EP3265051B1 Aqueous sun-related cosmetic composition free of surfactants NAOS LES LABORATOIRES 24 Mar, 2021
(Expiration: Mar, 2036)
BASF
(and 1 more)
EP2579835B1 Compositions for treating skin PROCTER AND GAMBLE CO 24 Mar, 2021
(Expiration: Jun, 2031)
HENKEL
EP2997134B1 Human application of engineered chimeric antigen receptor (car) t-cells UNIVERSITY OF TEXAS SYSTEM 24 Mar, 2021
(Expiration: May, 2034)
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
EP3409272B1 Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder ALFRED E TIEFENBACHER GMBH AND CO KG 23 Mar, 2021
(Expiration: Apr, 2038)
BLLE DR
EP3085386B1 Method for inhibiting bone resorption AMGEN INC 23 Mar, 2021
(Expiration: Sep, 2028)
JAMES POOLE
EP3228299B1 Novel sunscreen composition with a reduced textile staining BEIERSDORF AG 23 Mar, 2021
(Expiration: Mar, 2037)
LOREAL
EP3264917B1 Rebaudioside-d containing sweetener compositions HEARTLAND CONSUMER PRODUCTS LLC 22 Mar, 2021
(Expiration: Mar, 2036)
BUDDE SCHOU
EP3380198B1 Cosmetic composition comprising at least a powder exhibiting a low thermal conductivity CHANEL PARFUMS BEAUTE SAS 22 Mar, 2021
(Expiration: Nov, 2036)
TRSCH
EP2099453B1 Combination therapy of substituted oxazolidinones BAYER INTELLECTUAL PROPERTY GMBH 19 Mar, 2021
(Expiration: Oct, 2027)
ZENTIVA GROUP
(and 8 more)
EP3219328B1 Human anti-il-23 antibodies, compositions, method and uses JANSSEN BIOTECH INC 17 Mar, 2021
(Expiration: Dec, 2026)
BOEHRINGER INGELHEIM PHARMA
(and 1 more)
EP3068403B1 Methods of treatment of ocular conditions with a sustained drug delivery implant ALLERGAN INC 16 Mar, 2021
(Expiration: Nov, 2034)
DF MP DRRIES FRANK MOLNIA & POHLMAN
EP2822568B1 Uses of casein compositions FONTERRA COOPERATIVE GROUP LTD 16 Mar, 2021
(Expiration: Mar, 2033)
NUTRICIA
EP2493466B1 Novel antitumoral use of cabazitaxel SANOFI MATURE IP 10 Mar, 2021
(Expiration: Oct, 2030)
ACCORD HEALTHCARE
(and 11 more)
EP2328553B1 Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract UNIVERSITY OF CALIFORNIA 10 Mar, 2021
(Expiration: Nov, 2028)
AECHTER
EP3311791B1 Ethanol sunscreen composition with a reduced likelihood of discolouring textiles BEIERSDORF AG 10 Mar, 2021
(Expiration: Oct, 2037)
LOREAL
(and 2 more)
EP2793833B1 Topical oil composition for the treatment of fungal infections VYOME THERAPEUTICS LTD 04 Mar, 2021
(Expiration: Dec, 2032)
HENKEL
(and 2 more)
EP3453387B1 Dosage regimen for a s1p receptor agonist NOVARTIS AG 03 Mar, 2021
(Expiration: Dec, 2029)
LABORATORIOS LICONSA
(and 2 more)
EP3354253B1 Use of diethylaminohydroxybenzoylhexylbenzoate in cosmetic sunscreening compositions BEIERSDORF AG 03 Mar, 2021
(Expiration: Jan, 2038)
STADA ARZNEIMITTEL
(and 2 more)
EP2658549B1 Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents ABBOTT LABORATORIES 02 Mar, 2021
(Expiration: Dec, 2031)
SOCIT DES PRODUITS NESTL
(and 1 more)
EP3204047B1 Calcifediol soft capsules FAES FARMA SA 01 Mar, 2021
(Expiration: Feb, 2036)
DSM NUTRITIONAL PRODUCTS
(and 2 more)
EP3459356B1 Improved method for producing blood meal TESSENDERLO GROUP NV 01 Mar, 2021
(Expiration: Jan, 2038)
HAARSLEV INDUSTRIES
(and 3 more)
EP3093295B1 Il-15 heterogeneous dimer protein and uses thereof JIANGSU HENGRUI MEDICINE CO LTD 01 Mar, 2021
(Expiration: Dec, 2034)
MARGARET DIXON
EP2985016B1 Dental composite material having stable pasty property SHOFU INC 26 Feb, 2021
(Expiration: Jul, 2035)
IVOCLAR VIVADENT
(and 1 more)
EP2982361B1 Composite material having reduced degradation of pasty property SHOFU INC 26 Feb, 2021
(Expiration: Jul, 2035)
IVOCLAR VIVADENT
(and 1 more)
EP1591105B1 Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations STADA ARZNEIMITTEL AG 26 Feb, 2021
(Expiration: Mar, 2025)
MERCK PATENT
(and 5 more)
EP2233127B1 Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations STADA ARZNEIMITTEL AG 26 Feb, 2021
(Expiration: Mar, 2025)
MERCK PATENT
(and 7 more)
EP2723354B3 Compositions, uses, and preparation of platelet lysates EMORY UNIVERSITY 26 Feb, 2021
(Expiration: Jun, 2032)
PILLER
EP3443979B1 Il-2 dosage regimen for treating systemic lupus erythematosus ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP 26 Feb, 2021
(Expiration: Mar, 2032)
STRAWMAN
EP3320919B1 Multivalent pcv2 immunogenic compositions and methods of producing such compositions BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC 25 Feb, 2021
(Expiration: Dec, 2026)
ELANCO
(and 1 more)
EP2646003B1 Rapidly dispersing granules, orally disintegrating tablets and methods ADARE PHARMACEUTICALS INC 23 Feb, 2021
(Expiration: Dec, 2031)
DR FALK PHARMA
EP3256101B1 Solid anhydrous cosmetic composition, preparation process, cosmetic treatment processes and associated kit LOREAL SA 20 Feb, 2021
(Expiration: Dec, 2035)
HENKEL
EP2653162B1 Methods of administering fluvoxamine therapy INTERMUNE INC 19 Feb, 2021
(Expiration: Dec, 2030)
ALFRED E TIEFENBACHER
(and 3 more)
EP3346975B1 Process for semipermanent straightening and dyeing hair KAO GERMANY GMBH 19 Feb, 2021
(Expiration: Mar, 2036)
HENKEL
EP3086863B2 Cosmetic compositions and methods providing enhanced penetration of skin care actives PROCTER AND GAMBLE CO 19 Feb, 2021
(Expiration: Dec, 2034)
HENKEL
(and 1 more)
EP2815752B1 Oral pharmaceutical composition TAIHO PHARMACEUTICAL CO LTD 19 Feb, 2021
(Expiration: Feb, 2033)
TEVA PHARMACEUTICAL INDUSTRIES
EP3490526B1 Isotonic crystalloid aqueous solution INDIVIDUAL 12 Feb, 2021
(Expiration: Jul, 2037)
LABORATOIRES QUINTON
EP3135275B1 Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications JSC GRINDEKS 11 Feb, 2021
(Expiration: Aug, 2035)
BACHELIN
(and 2 more)
EP3253410B1 A vaccine for use against subclinical lawsonia infection in a pig INTERVET INTERNATIONAL BV 08 Feb, 2021
(Expiration: Feb, 2036)
BOEHRINGER INGELHEIM VETMEDICA
(and 1 more)
EP3223834B2 Probiotic and prebiotic compositions comprising blautia species for reducing inflammation EVELO BIOSCIENCES INC 08 Feb, 2021
(Expiration: Nov, 2035)
HGF
EP3253409B1 A vaccine for use against subclinical lawsonia infection in a pig INTERVET INTERNATIONAL BV 05 Feb, 2021
(Expiration: Feb, 2036)
CEVA SANTE ANIMALE
(and 1 more)
EP3057612B1 Method of obtaining thermostable dried vaccine formulations MERCK SHARP AND DOHME LLC 05 Feb, 2021
(Expiration: Oct, 2034)
GLAXO GROUP
EP2204157B1 Two-part hairdye composition KAO CORP 05 Feb, 2021
(Expiration: Oct, 2027)
HENKEL
EP3019610B1 Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP 05 Feb, 2021
(Expiration: Jul, 2034)
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
EP2797581B1 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione AMGEN EUROPE GMBH 05 Feb, 2021
(Expiration: Dec, 2032)
KRKA
(and 2 more)
EP3389691B1 Cyclic ntcp-targeting peptides and their uses as entry inhibitors UNIVERSITAET HEIDELBERG 05 Feb, 2021
(Expiration: Dec, 2036)
MARGARET DIXON
EP2641917B1 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) AMGEN INC 05 Feb, 2021
(Expiration: Aug, 2028)
SANOFI
EP2411048B1 Adjuvanting meningococcal factor h binding protein GLAXOSMITHKLINE BIOLOGICALS SA 05 Feb, 2021
(Expiration: Mar, 2030)
SANOFI PASTEUR
EP3062798B1 Modified rna with decreased immunostimulatory properties CUREVAC AG 05 Feb, 2021
(Expiration: Oct, 2034)
WEICKMANN & WEICKMANN PARTMBB
(and 1 more)
EP2506850B1 Methods of administering pirfenidone therapy INTERMUNE INC 03 Feb, 2021
(Expiration: Dec, 2030)
AERA
(and 5 more)
EP3528900B1 Compressed hair spray UNILEVER PLC 03 Feb, 2021
(Expiration: Oct, 2037)
LOREAL
EP3115047B1 Debility preventative AJINOMOTO CO INC 01 Feb, 2021
(Expiration: Mar, 2035)
FRESENIUS KABI DEUTSCHLAND
EP3178483B1 Composition for inducing proliferation or accumulation of regulatory t cells UNIVERSITY OF TOKYO NUC 29 Jan, 2021
(Expiration: Jun, 2031)
POTTER CLARKSON
(and 3 more)
EP3313372B1 Packaged silicone lubricated condom that provides sensation LIFESTYLES HEALTHCARE PTE LTD 29 Jan, 2021
(Expiration: May, 2036)
RECKITT BENCKISER HEALTH
EP3552613B1 Composition for inducing proliferation or accumulation of regulatory t cells UNIVERSITY OF TOKYO NUC 29 Jan, 2021
(Expiration: Jun, 2031)
STRAWMAN
(and 1 more)
EP3539548B1 Composition for inducing proliferation or accumulation of regulatory cells UNIVERSITY OF TOKYO NUC 29 Jan, 2021
(Expiration: Jun, 2031)
STRAWMAN
(and 3 more)
EP3558224B1 Use of chelating agents for improving color stability of resorcinol UNILEVER PLC 28 Jan, 2021
(Expiration: Nov, 2037)
HENKEL
EP2341905B2 Sustained release formulations using non-aqueous carriers AMYLIN PHARMACEUTICALS LLC 28 Jan, 2021
(Expiration: Sep, 2029)
INSTONE
EP3205334B1 Method and composition for treating ocular hypertension and glaucoma ASAHI GLASS CO LTD 26 Jan, 2021
(Expiration: May, 2029)
COOKE
EP3085683B1 Composition comprising an extract and bio-derived 1,3-propanediol as non irritating solvent DUPONT TATE AND LYLE BIO PRODUCTS CO LLC 26 Jan, 2021
(Expiration: Feb, 2027)
DSM NUTRITIONAL PRODUCTS
EP3260110B1 Aerosol hairspray product for styling and/or shaping hair PROCTER AND GAMBLE CO 22 Jan, 2021
(Expiration: Dec, 2031)
HENKEL
(and 1 more)
EP3287123B1 Aqueous pharmaceutical formulation of tapentadol for oral administration GRUENENTHAL GMBH 22 Jan, 2021
(Expiration: Mar, 2032)
LABOMED PHARMACEUTICAL COMPAMY
EP3421092B1 Anti-regurgitation composition preserving gut motility UNITED PHARMACEUTICALS SA 22 Jan, 2021
(Expiration: May, 2034)
NUTRICIA
EP3280416B1 Dosing regimen for missed doses for long-acting injectable paliperidone esters JANSSEN PHARMACEUTICALS INC 22 Jan, 2021
(Expiration: Mar, 2036)
STADA ARZNEIMITTEL
(and 7 more)
EP3111916B1 Use of charged surfactants for reducing textile staining by antiperspirants BEIERSDORF AG 22 Jan, 2021
(Expiration: Feb, 2030)
UNILEVER UNILEVER
(and 1 more)
EP3317281B1 Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide ACERTA PHARMA BV 21 Jan, 2021
(Expiration: Jul, 2036)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
EP3461478B1 Swallowable drug delivery device RANI THERAPEUTICS LLC 21 Jan, 2021
(Expiration: Dec, 2030)
NOVO NORDISK
EP2349321B1 Annexin and its use to treat inflammatory disorders LONDON HEALTH SCIENCES CENTRE RESEARCH INC 21 Jan, 2021
(Expiration: Oct, 2029)
STRAWMAN
EP2683382B1 Dosing regimens for the treatment of fabry disease AMICUS THERAPEUTICS INC 21 Jan, 2021
(Expiration: Mar, 2032)
TEVA PHARMACEUTICAL INDUSTRIES
EP2651442B1 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer UNIVERSITY OF MARYLAND AT BALTIMORE 20 Jan, 2021
(Expiration: Dec, 2031)
GEMOAB
(and 1 more)
EP2830573B1 Multi-compartment device for bleaching keratin fibres LOREAL SA 20 Jan, 2021
(Expiration: Mar, 2033)
HENKEL
EP3134095B1 Improved methods for manufacturing adoptive cell therapies BLUEBIRD BIO INC 19 Jan, 2021
(Expiration: Apr, 2035)
DEHNS
(and 2 more)
EP2968254B1 Methods of treating lung cancer ABRAXIS BIOSCIENCE LLC 19 Jan, 2021
(Expiration: Mar, 2034)
TEVA PHARMACEUTICAL INDUSTRIES
EP3336082B1 Cleavable lipids TRANSLATE BIO INC 15 Jan, 2021
(Expiration: Jun, 2032)
DILG
(and 1 more)
EP3045164B1 Aqueous pharmaceutical compositions containing borate-polyol complexes NOVARTIS AG 15 Jan, 2021
(Expiration: Jun, 2030)
GENERICS UK
EP2945628B1 Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer ARAGON PHARMACEUTICALS INC 15 Jan, 2021
(Expiration: Jan, 2034)
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
(and 3 more)
EP3137070B1 Krill oil preparations and their uses AKER BIOMARINE ANTARCTIC AS 15 Jan, 2021
(Expiration: Apr, 2035)
RIMFROST
EP3302715B1 Composition comprising a particular anionic associative polymer, a particular fixing polymer and a particular anionic polymer LOREAL SA 14 Jan, 2021
(Expiration: Jun, 2036)
HENKEL
EP2782588B1 Methods and compositions for the treatment of diabetes and related symptoms EMMAUS MEDICAL INC 14 Jan, 2021
(Expiration: Nov, 2032)
JAMES POOLE
EP3478807B1 Lubricating oil GREEN FRIX 14 Jan, 2021
(Expiration: Jun, 2037)
MICROS CHANGSHU LUBRICATION TECHNOLOGY
EP3307290B1 Dietary supplement SOCIETE DES PRODUITS NESTLE SA 13 Jan, 2021
(Expiration: Jun, 2036)
FRIESLANDCAMPINA NEDERLAND
(and 2 more)
EP2978419B1 Compositions for improving cell viability and methods of use thereof AMYLYX PHARMACEUTICALS INC 11 Jan, 2021
(Expiration: Feb, 2034)
BRUSCHETTINI
(and 1 more)
EP3003058B2 Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier PURECIRCLE USA INC 11 Jan, 2021
(Expiration: Jun, 2034)
CARGILL
EP2395983B1 Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH 11 Jan, 2021
(Expiration: Feb, 2030)
GENERICS UK
(and 2 more)
EP2785828B1 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells SCHOOL CORP AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION 11 Jan, 2021
(Expiration: Nov, 2032)
HGF
EP3087098B1 Anti-vista antibodies and fragments JANSSEN PHARMACEUTICA NV 09 Jan, 2021
(Expiration: Dec, 2034)
REGIMBEAU
(and 1 more)
EP3423028B1 Method for the production of encapsulated fragrance with improved stability against detergents SYMRISE AG 08 Jan, 2021
(Expiration: Feb, 2036)
FIRMENICH
(and 1 more)
EP2866825B1 Use of long-acting glp-1 peptides NOVO NORDISK AS 08 Jan, 2021
(Expiration: Jun, 2033)
GALENICUM HEALTH SLU
(and 2 more)
EP2961775B1 Pharmaceutical compositions with enhanced performance and improved processability HERCULES LLC 08 Jan, 2021
(Expiration: Feb, 2034)
SHIN ETSU CHEMICAL
EP2399588B1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase IONIS PHARMACEUTICALS INC 07 Jan, 2021
(Expiration: Jan, 2022)
GILEAD SCIENCES
EP2234963B1 Controlled release formulations of levodopa and uses thereof IMPAX LABORATORIES LLC 07 Jan, 2021
(Expiration: Dec, 2028)
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
EP3481363B1 Personal cleansing compositions UNILEVER PLC 06 Jan, 2021
(Expiration: Jul, 2037)
HENKEL